J&J found liable in Oklahoma opioid case and ordered to pay $572M; pledges to appeal

jnj
A judge in Oklahoma ordered J&J to pay $572M for its role in the state's opioid crisis. (J&J)

Johnson & Johnson fought hard against Oklahoma's claims the company played a "kingpin" role in the state’s opioid epidemic, but its lawyers fell short in those efforts after a six-week trial. On Monday, Judge Thad Balkman ruled that J&J created a public nuisance and ordered the company to pay $572 million as part of an opioid abatement plan. 

Oklahoma faces a “temporary public nuisance that can be abated,” Judge Balkman said as he read his decision on Monday. The $572 million verdict is the amount Balkman said he’s constrained to order based on the law and the evidence presented at trial. 

Previously, Oklahoma Department of Mental Health and Substance Abuse Commissioner Terri White testified the state’s opioid crisis will cost more than $17 billion to clean up. Prosecutors asked the judge to order J&J to pay that amount. If further funding is needed, Balkman said it'll be up to lawmakers to create abatement programs.

A J&J representative said the company plans to appeal the decision.  

RELATED: Should J&J owe billions for Oklahoma's opioid crisis? We'll find out Monday 

While the judge’s decision marked a loss for J&J, the company’s investors celebrated the news, as analysts saw a potential for a much larger verdict. Before the Monday decision, Wells Fargo analyst David Maris said his team expected a verdict of more than $2 billion. J&J shares jumped 4% after the market closed on Monday. 

Still, the case isn’t nearly as important as the multidistrict litigation in Cleveland, Ohio, Maris said on CNBC following the Monday decision. J&J and other defendants face thousands of lawsuits there in litigation that could generate a settlement in the tens of billions of dollars, Maris said. 

J&J's verdict comes in much higher than the settlements inked by Purdue and Teva before the Oklahoma trial of $270 million and $85 million, respectively. 

Read more on

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.